0000950170-25-094091.txt : 20250703 0000950170-25-094091.hdr.sgml : 20250703 20250703190304 ACCESSION NUMBER: 0000950170-25-094091 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20250701 FILED AS OF DATE: 20250703 DATE AS OF CHANGE: 20250703 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Treco Douglas A CENTRAL INDEX KEY: 0001688192 ORGANIZATION NAME: FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 251106723 MAIL ADDRESS: STREET 1: 87 CAMBRIDGEPARK DRIVE STREET 2: C/O RA PHARMACEUTICALS, INC. CITY: CAMBRIDGE STATE: MA ZIP: 02140 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences EIN: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 ownership.xml 4 X0508 4 2025-07-01 true 0001693011 Inozyme Pharma, Inc. INZY 0001688192 Treco Douglas A C/O INOZYME PHARMA, INC. 321 SUMMER STREET SUITE 400 BOSTON MA 02210 true true false false CEO & Chairman false Common Stock 2025-07-01 4 U false 43861 4.00 D 0 D Restricted Stock Units 2025-07-01 4 D false 150000 D Common Stock 150000 0 D Stock Option (Right to Buy) 2.77 2025-07-01 4 D false 86979 D 2030-05-27 Common Stock 86979 0 D Stock Option (Right to Buy) 1.06 2025-07-01 4 D false 400000 D 2035-03-10 Common Stock 400000 0 D This Form 4 reports securities disposed pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 16, 2025, by and among the Issuer, BioMarin Pharmaceutical Inc., a Delaware corporation ("Parent"), and Incline Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Merger Sub"). Pursuant to the Merger Agreement, Merger Sub completed a cash tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.0001 per share (the "Company Common Stock"), for a price per share of $4.00 (the "Merger Consideration"), without interest and subject to any withholding of taxes required by applicable law. Effective as of July 1, 2025, Merger Sub merged with and into the Issuer, with the Issuer continuing as the surviving corporation and as a wholly-owned subsidiary of Parent (the "Merger"). Pursuant to the terms of the Merger Agreement, at the effective time of the Merger (the "Effective Time"), each share of Company Common Stock held by the Reporting Person was tendered in exchange for the Merger Consideration, without interest and subject to any withholding of taxes required by applicable law. Pursuant to the terms of the Merger Agreement, each share of Company Common Stock subject to issuance pursuant to outstanding restricted stock units (each, a "Company RSU Award"), whether vested or unvested that was outstanding immediately prior to the Effective Time, was automatically accelerated, became fully vested, and was cancelled and automatically converted into the right to receive, for each share of Company Common Stock underlying such Company RSU Award, an amount (without interest and subject to deduction for any required withholding under applicable law relating to tax) in cash equal to the Merger Consideration. Pursuant to the terms of the Merger Agreement, each outstanding option to purchase shares of Company Common Stock ("Company Option"), whether vested or unvested, that was outstanding immediately prior to the Effective Time and had a per share exercise price that was less than the Merger Consideration was automatically accelerated and became fully vested, was cancelled and automatically converted into the right to receive for each share of Company Common Stock underlying such Company Option, an amount (without interest and subject to deduction for any required withholding under applicable law) in cash equal to the excess of the Merger Consideration over the per share exercise price of such Company Option. /s/ Sanjay Subramanian, as attorney-in-fact for Douglas A Treco 2025-07-03